Virios Therapeutics, Inc.
Virios Therapeutics, Inc. (VIRI) Stock Competitors & Peer Comparison
See (VIRI) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VIRI | $0.16 | +12.40% | 206.5K | -0.03 | -$5.75 | N/A |
| NVO | $44.74 | -2.31% | 198.7B | 10.38 | $4.31 | +4.05% |
| VRTX | $436.95 | -2.99% | 110.8B | 25.92 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $698.25 | -2.05% | 71.9B | 17.13 | $40.75 | +0.51% |
| ARGX | $799.32 | -2.77% | 49.5B | 35.56 | $22.48 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $286.98 | -2.20% | 38.3B | 71.92 | $3.99 | N/A |
| RVMD | $145.66 | -2.55% | 31B | -19.90 | -$7.32 | N/A |
| UTHR | $568.58 | -1.25% | 24.1B | 21.02 | $27.05 | N/A |
Stock Comparison
VIRI vs NVO Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, NVO has a market cap of 198.7B. Regarding current trading prices, VIRI is priced at $0.16, while NVO trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas NVO's P/E ratio is 10.38. In terms of profitability, VIRI's ROE is +3.40%, compared to NVO's ROE of +0.66%. Regarding short-term risk, VIRI is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check NVO's competition here
VIRI vs VRTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, VRTX has a market cap of 110.8B. Regarding current trading prices, VIRI is priced at $0.16, while VRTX trades at $436.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas VRTX's P/E ratio is 25.92. In terms of profitability, VIRI's ROE is +3.40%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, VIRI is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check VRTX's competition here
VIRI vs VRNA Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VIRI is priced at $0.16, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VIRI's ROE is +3.40%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, VIRI is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check VRNA's competition here
VIRI vs REGN Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, REGN has a market cap of 71.9B. Regarding current trading prices, VIRI is priced at $0.16, while REGN trades at $698.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas REGN's P/E ratio is 17.13. In terms of profitability, VIRI's ROE is +3.40%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VIRI is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check REGN's competition here
VIRI vs ARGX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ARGX has a market cap of 49.5B. Regarding current trading prices, VIRI is priced at $0.16, while ARGX trades at $799.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ARGX's P/E ratio is 35.56. In terms of profitability, VIRI's ROE is +3.40%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, VIRI is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ARGX's competition here
VIRI vs SGEN Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VIRI is priced at $0.16, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VIRI's ROE is +3.40%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VIRI is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check SGEN's competition here
VIRI vs ALNY Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ALNY has a market cap of 38.3B. Regarding current trading prices, VIRI is priced at $0.16, while ALNY trades at $286.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ALNY's P/E ratio is 71.92. In terms of profitability, VIRI's ROE is +3.40%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, VIRI is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ALNY's competition here
VIRI vs RVMD Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, RVMD has a market cap of 31B. Regarding current trading prices, VIRI is priced at $0.16, while RVMD trades at $145.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas RVMD's P/E ratio is -19.90. In terms of profitability, VIRI's ROE is +3.40%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, VIRI is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check RVMD's competition here
VIRI vs UTHR Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, UTHR has a market cap of 24.1B. Regarding current trading prices, VIRI is priced at $0.16, while UTHR trades at $568.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas UTHR's P/E ratio is 21.02. In terms of profitability, VIRI's ROE is +3.40%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VIRI is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check UTHR's competition here
VIRI vs INSM Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, INSM has a market cap of 23.7B. Regarding current trading prices, VIRI is priced at $0.16, while INSM trades at $109.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas INSM's P/E ratio is -18.95. In terms of profitability, VIRI's ROE is +3.40%, compared to INSM's ROE of -1.30%. Regarding short-term risk, VIRI is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check INSM's competition here
VIRI vs RPRX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, RPRX has a market cap of 22.7B. Regarding current trading prices, VIRI is priced at $0.16, while RPRX trades at $52.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas RPRX's P/E ratio is 27.82. In terms of profitability, VIRI's ROE is +3.40%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, VIRI is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check RPRX's competition here
VIRI vs BNTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, BNTX has a market cap of 22.6B. Regarding current trading prices, VIRI is priced at $0.16, while BNTX trades at $89.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas BNTX's P/E ratio is -15.05. In terms of profitability, VIRI's ROE is +3.40%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, VIRI is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check BNTX's competition here
VIRI vs ROIV Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ROIV has a market cap of 21B. Regarding current trading prices, VIRI is priced at $0.16, while ROIV trades at $29.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ROIV's P/E ratio is -25.03. In terms of profitability, VIRI's ROE is +3.40%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, VIRI is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ROIV's competition here
VIRI vs BGNE Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VIRI is priced at $0.16, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VIRI's ROE is +3.40%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, VIRI is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check BGNE's competition here
VIRI vs MRNA Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, MRNA has a market cap of 19.5B. Regarding current trading prices, VIRI is priced at $0.16, while MRNA trades at $49.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas MRNA's P/E ratio is -6.02. In terms of profitability, VIRI's ROE is +3.40%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, VIRI is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check MRNA's competition here
VIRI vs INCY Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, INCY has a market cap of 19B. Regarding current trading prices, VIRI is priced at $0.16, while INCY trades at $95.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas INCY's P/E ratio is 13.46. In terms of profitability, VIRI's ROE is +3.40%, compared to INCY's ROE of +0.29%. Regarding short-term risk, VIRI is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check INCY's competition here
VIRI vs DNA-WT Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VIRI is priced at $0.16, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VIRI's ROE is +3.40%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, VIRI is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check DNA-WT's competition here
VIRI vs GMAB Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, GMAB has a market cap of 16.3B. Regarding current trading prices, VIRI is priced at $0.16, while GMAB trades at $26.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas GMAB's P/E ratio is 20.26. In terms of profitability, VIRI's ROE is +3.40%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, VIRI is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check GMAB's competition here
VIRI vs NBIX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, NBIX has a market cap of 15.9B. Regarding current trading prices, VIRI is priced at $0.16, while NBIX trades at $158.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas NBIX's P/E ratio is 24.33. In terms of profitability, VIRI's ROE is +3.40%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, VIRI is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check NBIX's competition here
VIRI vs ASND Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ASND has a market cap of 14.9B. Regarding current trading prices, VIRI is priced at $0.16, while ASND trades at $240.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ASND's P/E ratio is 26.96. In terms of profitability, VIRI's ROE is +3.40%, compared to ASND's ROE of -56.42%. Regarding short-term risk, VIRI is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ASND's competition here
VIRI vs JAZZ Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, JAZZ has a market cap of 14.4B. Regarding current trading prices, VIRI is priced at $0.16, while JAZZ trades at $228.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas JAZZ's P/E ratio is 1906.42. In terms of profitability, VIRI's ROE is +3.40%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, VIRI is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check JAZZ's competition here
VIRI vs SMMT Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, SMMT has a market cap of 13.1B. Regarding current trading prices, VIRI is priced at $0.16, while SMMT trades at $16.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas SMMT's P/E ratio is -10.61. In terms of profitability, VIRI's ROE is +3.40%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, VIRI is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check SMMT's competition here
VIRI vs BBIO Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, VIRI is priced at $0.16, while BBIO trades at $66.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas BBIO's P/E ratio is -17.68. In terms of profitability, VIRI's ROE is +3.40%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, VIRI is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check BBIO's competition here
VIRI vs EXEL Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, VIRI is priced at $0.16, while EXEL trades at $50.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas EXEL's P/E ratio is 16.60. In terms of profitability, VIRI's ROE is +3.40%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, VIRI is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check EXEL's competition here
VIRI vs KRTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VIRI is priced at $0.16, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VIRI's ROE is +3.40%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VIRI is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check KRTX's competition here
VIRI vs IONS Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, IONS has a market cap of 12.3B. Regarding current trading prices, VIRI is priced at $0.16, while IONS trades at $74.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas IONS's P/E ratio is -36.93. In terms of profitability, VIRI's ROE is +3.40%, compared to IONS's ROE of -0.59%. Regarding short-term risk, VIRI is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check IONS's competition here
VIRI vs MDGL Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, VIRI is priced at $0.16, while MDGL trades at $523.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas MDGL's P/E ratio is -38.88. In terms of profitability, VIRI's ROE is +3.40%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, VIRI is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check MDGL's competition here
VIRI vs AXSM Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, AXSM has a market cap of 11.7B. Regarding current trading prices, VIRI is priced at $0.16, while AXSM trades at $227.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas AXSM's P/E ratio is -61.22. In terms of profitability, VIRI's ROE is +3.40%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, VIRI is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check AXSM's competition here
VIRI vs RNAM Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VIRI is priced at $0.16, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VIRI's ROE is +3.40%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VIRI is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check RNAM's competition here
VIRI vs ARWR Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ARWR has a market cap of 10.8B. Regarding current trading prices, VIRI is priced at $0.16, while ARWR trades at $76.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ARWR's P/E ratio is -33.78. In terms of profitability, VIRI's ROE is +3.40%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, VIRI is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ARWR's competition here
VIRI vs BMRN Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, BMRN has a market cap of 10B. Regarding current trading prices, VIRI is priced at $0.16, while BMRN trades at $51.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas BMRN's P/E ratio is 37.27. In terms of profitability, VIRI's ROE is +3.40%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, VIRI is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check BMRN's competition here
VIRI vs RXDX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VIRI is priced at $0.16, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VIRI's ROE is +3.40%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VIRI is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check RXDX's competition here
VIRI vs CYTK Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CYTK has a market cap of 9.4B. Regarding current trading prices, VIRI is priced at $0.16, while CYTK trades at $75.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CYTK's P/E ratio is -11.07. In terms of profitability, VIRI's ROE is +3.40%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, VIRI is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CYTK's competition here
VIRI vs KRYS Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, VIRI is priced at $0.16, while KRYS trades at $306.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas KRYS's P/E ratio is 41.00. In terms of profitability, VIRI's ROE is +3.40%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VIRI is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check KRYS's competition here
VIRI vs IMGN Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VIRI is priced at $0.16, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VIRI's ROE is +3.40%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VIRI is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check IMGN's competition here
VIRI vs BPMC Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VIRI is priced at $0.16, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VIRI's ROE is +3.40%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, VIRI is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check BPMC's competition here
VIRI vs IBRX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, VIRI is priced at $0.16, while IBRX trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas IBRX's P/E ratio is -9.38. In terms of profitability, VIRI's ROE is +3.40%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, VIRI is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check IBRX's competition here
VIRI vs CERE Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VIRI is priced at $0.16, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CERE's P/E ratio is -16.47. In terms of profitability, VIRI's ROE is +3.40%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VIRI is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CERE's competition here
VIRI vs HALO Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, HALO has a market cap of 8B. Regarding current trading prices, VIRI is priced at $0.16, while HALO trades at $67.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas HALO's P/E ratio is 23.55. In terms of profitability, VIRI's ROE is +3.40%, compared to HALO's ROE of +1.26%. Regarding short-term risk, VIRI is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check HALO's competition here
VIRI vs PCVX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, PCVX has a market cap of 7.6B. Regarding current trading prices, VIRI is priced at $0.16, while PCVX trades at $52.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas PCVX's P/E ratio is -7.57. In terms of profitability, VIRI's ROE is +3.40%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, VIRI is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check PCVX's competition here
VIRI vs NUVL Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, VIRI is priced at $0.16, while NUVL trades at $102.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas NUVL's P/E ratio is -16.88. In terms of profitability, VIRI's ROE is +3.40%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VIRI is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check NUVL's competition here
VIRI vs ABVX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, VIRI is priced at $0.16, while ABVX trades at $114.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ABVX's P/E ratio is -20.02. In terms of profitability, VIRI's ROE is +3.40%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, VIRI is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ABVX's competition here
VIRI vs MTSR Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VIRI is priced at $0.16, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VIRI's ROE is +3.40%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, VIRI is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check MTSR's competition here
VIRI vs PRAX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, PRAX has a market cap of 7.2B. Regarding current trading prices, VIRI is priced at $0.16, while PRAX trades at $342.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas PRAX's P/E ratio is -25.58. In terms of profitability, VIRI's ROE is +3.40%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, VIRI is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check PRAX's competition here
VIRI vs MRUS Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VIRI is priced at $0.16, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VIRI's ROE is +3.40%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, VIRI is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check MRUS's competition here
VIRI vs TECH Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, TECH has a market cap of 6.8B. Regarding current trading prices, VIRI is priced at $0.16, while TECH trades at $43.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas TECH's P/E ratio is 61.87. In terms of profitability, VIRI's ROE is +3.40%, compared to TECH's ROE of +0.05%. Regarding short-term risk, VIRI is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check TECH's competition here
VIRI vs KYMR Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, KYMR has a market cap of 6.8B. Regarding current trading prices, VIRI is priced at $0.16, while KYMR trades at $82.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas KYMR's P/E ratio is -22.96. In terms of profitability, VIRI's ROE is +3.40%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, VIRI is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check KYMR's competition here
VIRI vs ACLX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VIRI is priced at $0.16, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VIRI's ROE is +3.40%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VIRI is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ACLX's competition here
VIRI vs CELC Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CELC has a market cap of 6.7B. Regarding current trading prices, VIRI is priced at $0.16, while CELC trades at $137.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CELC's P/E ratio is -36.33. In terms of profitability, VIRI's ROE is +3.40%, compared to CELC's ROE of -2.45%. Regarding short-term risk, VIRI is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CELC's competition here
VIRI vs PTGX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, VIRI is priced at $0.16, while PTGX trades at $102.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas PTGX's P/E ratio is -56.45. In terms of profitability, VIRI's ROE is +3.40%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, VIRI is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check PTGX's competition here
VIRI vs RETA Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VIRI is priced at $0.16, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas RETA's P/E ratio is -66.29. In terms of profitability, VIRI's ROE is +3.40%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VIRI is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check RETA's competition here
VIRI vs ALKS Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ALKS has a market cap of 6.2B. Regarding current trading prices, VIRI is priced at $0.16, while ALKS trades at $37.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ALKS's P/E ratio is 41.64. In terms of profitability, VIRI's ROE is +3.40%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, VIRI is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ALKS's competition here
VIRI vs RYTM Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, VIRI is priced at $0.16, while RYTM trades at $90.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas RYTM's P/E ratio is -28.94. In terms of profitability, VIRI's ROE is +3.40%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, VIRI is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check RYTM's competition here
VIRI vs CNTA Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CNTA has a market cap of 6.1B. Regarding current trading prices, VIRI is priced at $0.16, while CNTA trades at $39.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CNTA's P/E ratio is -22.24. In terms of profitability, VIRI's ROE is +3.40%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VIRI is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CNTA's competition here
VIRI vs CORT Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CORT has a market cap of 6.1B. Regarding current trading prices, VIRI is priced at $0.16, while CORT trades at $56.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CORT's P/E ratio is 161.06. In terms of profitability, VIRI's ROE is +3.40%, compared to CORT's ROE of +0.08%. Regarding short-term risk, VIRI is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CORT's competition here
VIRI vs TGTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, TGTX has a market cap of 6B. Regarding current trading prices, VIRI is priced at $0.16, while TGTX trades at $39.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas TGTX's P/E ratio is 13.81. In terms of profitability, VIRI's ROE is +3.40%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, VIRI is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check TGTX's competition here
VIRI vs PTCT Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, PTCT has a market cap of 5.9B. Regarding current trading prices, VIRI is priced at $0.16, while PTCT trades at $71.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas PTCT's P/E ratio is -28.14. In terms of profitability, VIRI's ROE is +3.40%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, VIRI is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check PTCT's competition here
VIRI vs SRRK Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, VIRI is priced at $0.16, while SRRK trades at $49.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas SRRK's P/E ratio is -14.30. In terms of profitability, VIRI's ROE is +3.40%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, VIRI is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check SRRK's competition here
VIRI vs CGON Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, VIRI is priced at $0.16, while CGON trades at $66.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CGON's P/E ratio is -28.60. In terms of profitability, VIRI's ROE is +3.40%, compared to CGON's ROE of -0.23%. Regarding short-term risk, VIRI is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CGON's competition here
VIRI vs BLTE Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, BLTE has a market cap of 5.7B. Regarding current trading prices, VIRI is priced at $0.16, while BLTE trades at $143.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas BLTE's P/E ratio is -61.90. In terms of profitability, VIRI's ROE is +3.40%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, VIRI is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check BLTE's competition here
VIRI vs CDTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VIRI is priced at $0.16, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VIRI's ROE is +3.40%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, VIRI is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CDTX's competition here
VIRI vs IMVT Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, IMVT has a market cap of 5.6B. Regarding current trading prices, VIRI is priced at $0.16, while IMVT trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas IMVT's P/E ratio is -10.30. In terms of profitability, VIRI's ROE is +3.40%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, VIRI is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check IMVT's competition here
VIRI vs COGT Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, COGT has a market cap of 5.6B. Regarding current trading prices, VIRI is priced at $0.16, while COGT trades at $32.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas COGT's P/E ratio is -15.06. In terms of profitability, VIRI's ROE is +3.40%, compared to COGT's ROE of -0.83%. Regarding short-term risk, VIRI is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check COGT's competition here
VIRI vs ABCM Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VIRI is priced at $0.16, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VIRI's ROE is +3.40%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VIRI is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ABCM's competition here
VIRI vs ISEE Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VIRI is priced at $0.16, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VIRI's ROE is +3.40%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VIRI is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ISEE's competition here
VIRI vs APLS Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VIRI is priced at $0.16, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas APLS's P/E ratio is 38.35. In terms of profitability, VIRI's ROE is +3.40%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VIRI is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check APLS's competition here
VIRI vs FBIOX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, VIRI is priced at $0.16, while FBIOX trades at $24.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas FBIOX's P/E ratio is N/A. In terms of profitability, VIRI's ROE is +3.40%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, VIRI is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check FBIOX's competition here
VIRI vs MIRM Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, VIRI is priced at $0.16, while MIRM trades at $102.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas MIRM's P/E ratio is -7.51. In terms of profitability, VIRI's ROE is +3.40%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, VIRI is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check MIRM's competition here
VIRI vs LEGN Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, LEGN has a market cap of 5.1B. Regarding current trading prices, VIRI is priced at $0.16, while LEGN trades at $27.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas LEGN's P/E ratio is -19.96. In terms of profitability, VIRI's ROE is +3.40%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, VIRI is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check LEGN's competition here
VIRI vs LQDA Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, LQDA has a market cap of 5.1B. Regarding current trading prices, VIRI is priced at $0.16, while LQDA trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas LQDA's P/E ratio is 334.88. In terms of profitability, VIRI's ROE is +3.40%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, VIRI is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check LQDA's competition here
VIRI vs APGE Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, APGE has a market cap of 5B. Regarding current trading prices, VIRI is priced at $0.16, while APGE trades at $81.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas APGE's P/E ratio is -18.74. In terms of profitability, VIRI's ROE is +3.40%, compared to APGE's ROE of -0.33%. Regarding short-term risk, VIRI is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check APGE's competition here
VIRI vs TERN Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VIRI is priced at $0.16, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas TERN's P/E ratio is -51.41. In terms of profitability, VIRI's ROE is +3.40%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VIRI is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check TERN's competition here
VIRI vs CRSP Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, VIRI is priced at $0.16, while CRSP trades at $48.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CRSP's P/E ratio is -7.85. In terms of profitability, VIRI's ROE is +3.40%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, VIRI is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CRSP's competition here
VIRI vs FOLD Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VIRI is priced at $0.16, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VIRI's ROE is +3.40%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VIRI is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check FOLD's competition here
VIRI vs SYRE Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, SYRE has a market cap of 4.5B. Regarding current trading prices, VIRI is priced at $0.16, while SYRE trades at $74.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas SYRE's P/E ratio is -35.36. In terms of profitability, VIRI's ROE is +3.40%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, VIRI is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check SYRE's competition here
VIRI vs AKRO Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VIRI is priced at $0.16, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VIRI's ROE is +3.40%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, VIRI is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check AKRO's competition here
VIRI vs ALPN Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VIRI is priced at $0.16, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VIRI's ROE is +3.40%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VIRI is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ALPN's competition here
VIRI vs XENE Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, VIRI is priced at $0.16, while XENE trades at $54.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas XENE's P/E ratio is -11.57. In terms of profitability, VIRI's ROE is +3.40%, compared to XENE's ROE of -0.49%. Regarding short-term risk, VIRI is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check XENE's competition here
VIRI vs LGND Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, LGND has a market cap of 4.3B. Regarding current trading prices, VIRI is priced at $0.16, while LGND trades at $213.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas LGND's P/E ratio is 27.83. In terms of profitability, VIRI's ROE is +3.40%, compared to LGND's ROE of +0.16%. Regarding short-term risk, VIRI is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check LGND's competition here
VIRI vs KNSA Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, KNSA has a market cap of 4.2B. Regarding current trading prices, VIRI is priced at $0.16, while KNSA trades at $56.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas KNSA's P/E ratio is 62.10. In terms of profitability, VIRI's ROE is +3.40%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, VIRI is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check KNSA's competition here
VIRI vs OPT Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VIRI is priced at $0.16, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas OPT's P/E ratio is -1.52. In terms of profitability, VIRI's ROE is +3.40%, compared to OPT's ROE of +0.88%. Regarding short-term risk, VIRI is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check OPT's competition here
VIRI vs NAMS Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, NAMS has a market cap of 4.1B. Regarding current trading prices, VIRI is priced at $0.16, while NAMS trades at $35.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas NAMS's P/E ratio is -19.91. In terms of profitability, VIRI's ROE is +3.40%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, VIRI is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check NAMS's competition here
VIRI vs MANE Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, VIRI is priced at $0.16, while MANE trades at $99.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas MANE's P/E ratio is -41.91. In terms of profitability, VIRI's ROE is +3.40%, compared to MANE's ROE of -0.76%. Regarding short-term risk, VIRI is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check MANE's competition here
VIRI vs MRTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VIRI is priced at $0.16, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VIRI's ROE is +3.40%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VIRI is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check MRTX's competition here
VIRI vs CAI Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CAI has a market cap of 4.1B. Regarding current trading prices, VIRI is priced at $0.16, while CAI trades at $14.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CAI's P/E ratio is -5.27. In terms of profitability, VIRI's ROE is +3.40%, compared to CAI's ROE of +0.06%. Regarding short-term risk, VIRI is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CAI's competition here
VIRI vs TVTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, VIRI is priced at $0.16, while TVTX trades at $42.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas TVTX's P/E ratio is -85.18. In terms of profitability, VIRI's ROE is +3.40%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, VIRI is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check TVTX's competition here
VIRI vs CRNX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, VIRI is priced at $0.16, while CRNX trades at $36.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CRNX's P/E ratio is -7.15. In terms of profitability, VIRI's ROE is +3.40%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VIRI is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CRNX's competition here
VIRI vs CPRX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, VIRI is priced at $0.16, while CPRX trades at $31.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CPRX's P/E ratio is 18.02. In terms of profitability, VIRI's ROE is +3.40%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VIRI is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CPRX's competition here
VIRI vs RYZB Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VIRI is priced at $0.16, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VIRI's ROE is +3.40%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VIRI is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check RYZB's competition here
VIRI vs CBAY Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VIRI is priced at $0.16, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VIRI's ROE is +3.40%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VIRI is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check CBAY's competition here
VIRI vs ACAD Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, VIRI is priced at $0.16, while ACAD trades at $21.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ACAD's P/E ratio is 9.68. In terms of profitability, VIRI's ROE is +3.40%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, VIRI is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ACAD's competition here
VIRI vs DNTH Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, DNTH has a market cap of 3.6B. Regarding current trading prices, VIRI is priced at $0.16, while DNTH trades at $86.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas DNTH's P/E ratio is -20.37. In terms of profitability, VIRI's ROE is +3.40%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, VIRI is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check DNTH's competition here
VIRI vs TLX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, VIRI is priced at $0.16, while TLX trades at $10.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas TLX's P/E ratio is -528.00. In terms of profitability, VIRI's ROE is +3.40%, compared to TLX's ROE of -0.02%. Regarding short-term risk, VIRI is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check TLX's competition here
VIRI vs EWTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, VIRI is priced at $0.16, while EWTX trades at $33.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas EWTX's P/E ratio is -19.93. In terms of profitability, VIRI's ROE is +3.40%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, VIRI is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check EWTX's competition here
VIRI vs SWTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, VIRI is priced at $0.16, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas SWTX's P/E ratio is -13.78. In terms of profitability, VIRI's ROE is +3.40%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, VIRI is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check SWTX's competition here
VIRI vs VKTX Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, VIRI is priced at $0.16, while VKTX trades at $30.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas VKTX's P/E ratio is -7.29. In terms of profitability, VIRI's ROE is +3.40%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, VIRI is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check VKTX's competition here
VIRI vs ERAS Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, ERAS has a market cap of 3.2B. Regarding current trading prices, VIRI is priced at $0.16, while ERAS trades at $10.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas ERAS's P/E ratio is -11.00. In terms of profitability, VIRI's ROE is +3.40%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, VIRI is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check ERAS's competition here
VIRI vs NAMSW Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, NAMSW has a market cap of 3.1B. Regarding current trading prices, VIRI is priced at $0.16, while NAMSW trades at $27.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas NAMSW's P/E ratio is N/A. In terms of profitability, VIRI's ROE is +3.40%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, VIRI is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check NAMSW's competition here
VIRI vs VCYT Comparison May 2026
VIRI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIRI stands at 206.5K. In comparison, VCYT has a market cap of 3.1B. Regarding current trading prices, VIRI is priced at $0.16, while VCYT trades at $38.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIRI currently has a P/E ratio of -0.03, whereas VCYT's P/E ratio is 35.63. In terms of profitability, VIRI's ROE is +3.40%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, VIRI is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for VIRI.Check VCYT's competition here